• Consensus Rating: Hold
  • Consensus Price Target: $5.33
  • Forecasted Upside: 1,739.08%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.29
▼ -0.01 (-3.33%)

This chart shows the closing price for LIAN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LianBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LIAN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LIAN

Analyst Price Target is $5.33
▲ +1,739.08% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for LianBio in the last 3 months. The average price target is $5.33, with a high forecast of $9.00 and a low forecast of $3.00. The average price target represents a 1,739.08% upside from the last price of $0.29.

This chart shows the closing price for LIAN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in LianBio. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/29/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2024Bank of AmericaDowngradeBuy ➝ Underperform$5.00 ➝ $3.00Low
12/22/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$7.00 ➝ $4.00Low
10/25/2023Raymond JamesLower TargetOutperform ➝ Outperform$15.00 ➝ $9.00Low
10/14/2022Raymond JamesLower TargetOutperform$27.00 ➝ $15.00Low
11/26/2021Bank of AmericaInitiated CoverageBuyHigh
11/26/2021The Goldman Sachs GroupInitiated CoverageNeutral$18.58High
11/26/2021Jefferies Financial GroupInitiated CoverageBuy$24.00High
11/24/2021Raymond JamesInitiated CoverageOutperform$27.00High
(Data available from 4/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/23/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
LianBio logo
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $0.29
Low: $0.29
High: $0.29

50 Day Range

MA: $2.47
Low: $0.29
High: $4.99

52 Week Range

Now: $0.29
Low: $0.27
High: $4.99

Volume

5,547 shs

Average Volume

1,037,083 shs

Market Capitalization

$31.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Frequently Asked Questions

What sell-side analysts currently cover shares of LianBio?

The following Wall Street analysts have issued stock ratings on LianBio in the last twelve months: Bank of America Co., Jefferies Financial Group Inc., and Raymond James.
View the latest analyst ratings for LIAN.

What is the current price target for LianBio?

3 Wall Street analysts have set twelve-month price targets for LianBio in the last year. Their average twelve-month price target is $5.33, suggesting a possible upside of 1,739.1%. Raymond James has the highest price target set, predicting LIAN will reach $9.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $3.00 for LianBio in the next year.
View the latest price targets for LIAN.

What is the current consensus analyst rating for LianBio?

LianBio currently has 1 sell rating, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LIAN, but not buy more shares or sell existing shares.
View the latest ratings for LIAN.

What other companies compete with LianBio?

How do I contact LianBio's investor relations team?

The company's listed phone number is 609-486-2308 and its investor relations email address is [email protected]. The official website for LianBio is www.lianbio.com. Learn More about contacing LianBio investor relations.